OOIR: Observatory of International Research

Papers

(The H4-Index of Regulatory Toxicology and Pharmacology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Regulatory landscape of dietary supplements and herbal medicines from a global perspective	107
Regulatory landscape of nanotechnology and nanoplastics from a global perspective	100
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)	95
Updating exposure assessment for skin sensitization quantitative risk assessment for fragrance materials	81
Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data	71
Pulmonary toxicity of silver vapours, nanoparticles and fine dusts: A review	58
Butylated hydroxyanisole: Carcinogenic food additive to be avoided or harmless antioxidant important to protect food supply?	58
Toxicity of boric acid, borax and other boron containing compounds: A review	54
Review of regulatory reference values and background levels for heavy metals in the human diet	48
Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients	46
Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology	46
Human health hazard assessment of quaternary ammonium compounds: Didecyl dimethyl ammonium chloride and alkyl (C12–C16) dimethyl benzyl ammonium chloride	45
Can we define a level of protection for allergic consumers that everyone can accept?	42
Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients	39
Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats	38
“Natural” is not synonymous with “Safe”: Toxicity of natural products alone and in combination with pharmaceutical agents	38
Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER)	37
Occupational exposure to hexavalent chromium. Part II. Hazard assessment of carcinogenic effects	36
Toxicological evaluation of exosomes derived from human adipose tissue-derived mesenchymal stem/stromal cells	35
New ideas for non-animal approaches to predict repeated-dose systemic toxicity: Report from an EPAA Blue Sky Workshop	33
PBPK model reporting template for chemical risk assessment applications	32
Occupational exposure to hexavalent chromium. Part I. Hazard assessment of non-cancer health effects	32
A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment	32
Skin sensitization in silico protocol	30
Use of New Approach Methodologies (NAMs) in regulatory decisions for chemical safety: Report from an EPAA Deep Dive Workshop	30

Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds	29
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture	29
Reflections on the OECD guidelines for in vitro skin absorption studies	28